Biotage AB Nomination Committee

Biotage AB Nomination Committee 

A Nomination Committee consisting of shareholder representatives and the
Chairman of the Board of Directors has been formed for Biotage AB. The
Nomination Committee shall, before the Annual General Meeting 2009, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of Chairman of the Annual General Meeting, the
determination of fees and matters pertaining thereto.
The members of the Nomination Committee are:
Björn Odlander, HealthCap 

Karl Swartling, Investor Growth Capital

Carl Rosén, 2 AP-fonden
Ove Mattsson, Chairman of the Board

Shareholders wishing to submit a proposal for members of the Board of Directors
may do so sending e-mail to the Chairman of the Board of Directors of Biotage AB
at info@eu.biotage.com.
Contact:									
Torben Jörgensen, President and CEO					
Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com 
Kungsgatan 76
SE-753 18 Uppsala
Tel+46 18 56 59 00
www.biotage.com

About Biotage 
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 operations and products were acquired
from the American company Argonaut, further strengthening the medicinal
chemistry product range. The customers include the worlds top 30 pharmaceutical
companies, the worlds top 20 biotech companies, and leading academic institutes.
The company is headquartered in Uppsala and has offices in the U.S., Japan, UK,
Germany and several other European countries. Biotage has 336 employees and had
sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange
Stockholm AB. Website: www.biotage.com